Methods Of Using Sustained Release Aminopyridine Compositions

Patent No. EP2377536 (titled "Methods Of Using Sustained Release Aminopyridine Compositions") was filed by Acorda Therapeutics on Apr 11, 2005. The application was issued on Aug 17, 2022.

Patent Summary

A sustained-release oral dosage form of 4-aminopyridine (4-AP) for treating multiple sclerosis (MS) and other neurological disorders. The composition comprises 4-AP dispersed in a sustained-release matrix that maintains therapeutic plasma levels for at least 6 hours, preferably 12 hours, while minimizing peak and trough fluctuations. The dosage form is administered twice daily at 10 mg per dose, which has been shown to improve walking speed in MS patients while reducing adverse effects compared to immediate-release formulations.

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_COA_0000917/2025Dec 8, 2025Merz Pharmaceuticals, Merz Pharma FranceAppeal
UPC_COA_0000906/2025Nov 13, 2025Viatris SanteAppeal
UPC_CFI_697/2025Jul 31, 2025Merz Pharmaceuticals, Merz Pharma FranceProvisional Measures

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
NEURAXPHARM ARZNEIMITTELDec 6, 2013KONIGER
SYNTHONDec 6, 2013PRINS
ACTAVIS GROUP PTC EHFDec 5, 2013ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2377536

ACORDA THERAPEUTICS
Application Number
EP11160247A
Filing Date
Apr 11, 2005
Status
Patent Maintained As Amended
Jul 15, 2022
Publication Date
Aug 17, 2022